Depressions that are accompanied by anxiety, asthenia, and loss of initiative. Chronic neurotic disorders accompanied by anxiety, depression, and inactivity. Psychosomatic disorders with asthenic reactions. Schizophrenia and other psychoses, especially with symptoms such as hallucinations, delusions, and thinking disorders complicated by apathy, anergia, depressed mood, and seclusion.
Fluanxol 1 mg Storage
active substance: flupentixol;
1 tablet contains flupentixol dihydrochloride equivalent to 0.5 mg or 1 mg of flupentixol;
excipients: betadex; lactose monohydrate; corn starch; hydroxypropylcellulose; microcrystalline cellulose; croscarmellose sodium; talc; hydrogenated vegetable oil; magnesium stearate;
shell: polyvinyl alcohol partially hydrolyzed, titanium dioxide (E 171), macrogol 3350, talc, iron oxide yellow (E 172), macrogol 6000.
Fluanxol 1 mg Dosage form
Basic physical and chemical properties:
0.5 mg: round, slightly biconvex, yellow, film-coated tablets marked FD; 1 mg: oval, slightly biconvex, yellow, film-coated tablets marked FF.
Fluanxol 1 mg Pharmacotherapeutic group
Psycholeptics. Antipsychotics. Thioxanthene derivatives. Flupentixol.
ATX code N05A F01.
Flupentixol is a thioxanthene neuroleptic.
Flupentixol is a mixture of two geometric isomers, active flupentixol and trans (E) -flupentixol, in a ratio of approximately 1: 1.
The antipsychotic effect of neuroleptics has been associated with dopamine receptor blockade and possible 5HT receptor blockade. In vitro and in vivo, flupentixol has a high affinity for both dopamine D1 and D2 receptors in contrast to flufenazine, which is selective for D2 in vivo. The atypical antipsychotic clozapine has a flupentixol-like affinity for D1 and D2 receptors in vitro and in vivo.
Flupentixol has a high affinity for α1-adrenoceptors and 5HT2-receptors, although slightly lower than chlorprothixene, high-dose phenothiazines and clozapine, but has no affinity for cholinergic muscarinic receptors. It exhibits weak antihistaminergic properties and has no blocking effect on α2-adrenoceptors.
Flupentixol is a potent neuroleptic, as evidenced by all behavioral studies of neuroleptic activity (the ability to block dopamine receptors). At the average daily dosage and oral use for antipsychotic treatment, there is a related
Depression accompanied by anxiety, asthenia and loss of initiative.
Chronic neurotic disorders accompanied by anxiety, depression and inactivity.
Psychosomatic disorders with asthenic reactions.
Schizophrenia and other psychoses, especially with symptoms such as hallucinations, delusions, and thought disorders, are complicated by apathy, anergy, depressed mood, and loneliness.
Hypersensitivity to any component of the drug.
Severe depression requiring electroshock therapy or hospitalization; states of emotional agitation or hyperactivity, including mania.
Circulatory collapse, depression of the central nervous system of any origin (for example, due to alcohol, barbiturate or opioid intoxication), coma.
Not recommended for use in mildly excitable patients and in patients with a state of nervous excitement.